Defining the Pathogenic Contribution of High Genotypic MIF Expression

定义高基因型 MIF 表达的致病贡献

基本信息

  • 批准号:
    10402761
  • 负责人:
  • 金额:
    $ 36.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Rheumatoid arthritis (RA) remains incurable despite biologic therapies. We previously identified a functional promoter polymorphism in the gene for macrophage migration inhibitory factor (MIF) - a cytokine our group first cloned, that is associated with erosive joint destruction in RA. MIF is known to regulate the innate response by inhibiting glucocorticoid action, suppressing activation-induced apoptosis, and promoting macrophage retention in tissues. The role of MIF and high expression MIF alleles is not fully understood however, especially with respect to alterations in the adaptive response that perpetuate inflammation, pathologic progression, and disease persistence. We have discovered a novel T cell subpopulation that expresses the MIF receptor (CD74), expands during arthritis, and recapitulates disease when transferred into naïve hosts. A similar population exists in human rheumatoid synovium. We hypothesize that CD4+CD74+ T cells play a key role in rheumatoid inflammation, disease progression, and relapse. We will pursue three Specific Aims in this proposal: 1. Define the pathogenic role of a novel, MIF receptor expressing T cell sub-population (CD4+CD74+ T cells) in inflammatory arthritis. We hypothesize that CD4+CD74+ T cells express inflammatory cytokines and chemotactic receptors that contribute to synovial joint destruction. We will characterize the MIF signaling and effector responses of mouse and human CD4+CD74+ T cells, identify trafficking factors/receptors, and establish their pathogenic potential. 2. Define the impact of high-genotypic MIF expression on joint immunopathology in a novel humanized MIF mouse model. We hypothesize that MIF expression drives pathologic CD4+CD74+ T cell trafficking and effector responses, and unremitting arthritis. We will test this hypothesis using novel humanized MIF mice that express low-expression and high-expression human MIF alleles. 3. Evaluate the impact of ICBP90 inhibition on MIF expression in humanized MIF mice and in high genotypic MIF expressing human cells. We identified both the transcription factor (ICBP90) that upregulates MIF transcription at its variant promoter microsatellite (-794 CATT5-8), and a drug-like molecule (CMFT) that blocks ICBP90 binding to this promoter site. We hypothesize that ICBP90 inhibition will ameliorate the MIF- dependent expansion and effector response of CD4+CD74+ T cells. We will test this possibility in experimental arthritis and examine ICBP90 inhibition in high-genotypic MIF expressing human cells obtained from peripheral blood and from rheumatoid synovial tissue. The completion of these Aims will provide insight into the pathologic role of a novel, MIF receptor expressing T cell population and the contribution of MIF risk alleles to rheumatoid inflammation. These studies also will accelerate consideration of a precision-based approach for treating RA joint destruction.
项目摘要 风湿性关节炎(RA)仍然无法治愈,尽管生物疗法。我们之前发现了一个 巨噬细胞移动抑制因子基因功能启动子多态性 本课题组首次克隆了与类风湿关节炎关节破坏有关的基因。众所周知,MIF调节 通过抑制糖皮质激素作用,抑制活化诱导的细胞凋亡, 促进巨噬细胞滞留在组织中。MIF及其高表达等位基因的作用尚不完全 然而,理解,特别是在适应性反应的改变, 炎症、病理进展和疾病持续性。我们发现了一种新的T细胞 表达MIF受体(CD 74)的亚群,在关节炎期间扩增,并重现疾病 当转移到幼稚宿主体内时在人类类风湿性滑膜中也存在类似的群体。我们 假设CD 4 + CD 74 + T细胞在类风湿性炎症、疾病进展和 复发我们将在这项建议中追求三个具体目标:1。定义小说的致病作用, 炎症性关节炎中表达MIF受体的T细胞亚群(CD 4 + CD 74 + T细胞)。我们 假设CD 4 + CD 74 + T细胞表达炎性细胞因子和趋化性受体, 导致滑膜关节破坏。我们将描述的MIF信号和效应器的反应, 小鼠和人CD 4 + CD 74 + T细胞,鉴定运输因子/受体,并确定其致病性 潜力2.明确高基因型MIF表达对关节免疫病理学的影响, 新型人源化MIF小鼠模型。我们假设MIF表达驱动病理性CD 4 + CD 74 + T细胞运输和效应反应与持续性关节炎。我们将使用新的方法来验证这一假设。 人源化MIF小鼠,其表达低表达和高表达人MIF等位基因。3.评价 ICBP 90抑制对人源化MIF小鼠和高基因型MIF中MIF表达影响 表达人类细胞。我们鉴定了上调MIF的转录因子(ICBP 90)和 在其变体启动子微卫星(-794 CATT 5 -8)处转录,以及一种药物样分子(CMFT), 阻断ICBP 90与该启动子位点的结合。我们假设ICBP 90抑制将改善MIF- CD 4 + CD 74 + T细胞的依赖性扩增和效应子应答。我们将测试这种可能性, 实验性关节炎,并在表达高基因型MIF的人细胞中检测ICBP 90抑制 从外周血和类风湿性滑膜组织中获得。这些目标的完成将 提供了一种新的,表达MIF受体的T细胞群的病理作用的见解, MIF风险等位基因对类风湿性炎症的贡献。这些研究也将加速考虑 治疗RA关节破坏的精确方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD J BUCALA其他文献

RICHARD J BUCALA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD J BUCALA', 18)}}的其他基金

Defining the Pathogenic Contribution of High Genotypic MIF Expression
定义高基因型 MIF 表达的致病贡献
  • 批准号:
    10624334
  • 财政年份:
    2021
  • 资助金额:
    $ 36.48万
  • 项目类别:
Defining the Pathogenic Contribution of High Genotypic MIF Expression
定义高基因型 MIF 表达的致病贡献
  • 批准号:
    10094724
  • 财政年份:
    2021
  • 资助金额:
    $ 36.48万
  • 项目类别:
Aging and Innate Immune Mechanisms in Pulmonary Infection
肺部感染的衰老和先天免疫机制
  • 批准号:
    9300969
  • 财政年份:
    2015
  • 资助金额:
    $ 36.48万
  • 项目类别:
Aging and Innate Immune Mechanisms in Pulmonary Infection
肺部感染的衰老和先天免疫机制
  • 批准号:
    8967869
  • 财政年份:
    2015
  • 资助金额:
    $ 36.48万
  • 项目类别:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
疟原虫 MIF 对适应性免疫的炎症抑制
  • 批准号:
    10386832
  • 财政年份:
    2014
  • 资助金额:
    $ 36.48万
  • 项目类别:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
疟原虫 MIF 对适应性免疫的炎症抑制
  • 批准号:
    8664206
  • 财政年份:
    2014
  • 资助金额:
    $ 36.48万
  • 项目类别:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
疟原虫 MIF 对适应性免疫的炎症抑制
  • 批准号:
    8822823
  • 财政年份:
    2014
  • 资助金额:
    $ 36.48万
  • 项目类别:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
疟原虫 MIF 对适应性免疫的炎症抑制
  • 批准号:
    9815245
  • 财政年份:
    2014
  • 资助金额:
    $ 36.48万
  • 项目类别:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
疟原虫 MIF 对适应性免疫的炎症抑制
  • 批准号:
    10614419
  • 财政年份:
    2014
  • 资助金额:
    $ 36.48万
  • 项目类别:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
疟原虫 MIF 对适应性免疫的炎症抑制
  • 批准号:
    9036321
  • 财政年份:
    2014
  • 资助金额:
    $ 36.48万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 36.48万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 36.48万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 36.48万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 36.48万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 36.48万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 36.48万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 36.48万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 36.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 36.48万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 36.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了